|
|
 |
|
Viewing report
|
|
|
|
Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, Nov 2011, Pages: 71
Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global brain hemorrhage therapeutics market. The report identifies the key trends shaping and driving the global brain hemorrhage therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global brain hemorrhage sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global brain hemorrhage therapeutics market was worth $358m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 3% to $452m by 2018. The slow growth in the brain hemorrhage therapeutics market is largely due to its stable prevalence, a high mortality rate and a weak pipeline of only two company sponsored drugs. The main risk factors associated with brain hemorrhage are lifestyle factors such as smoking, obesity and alcohol consumption. The most common therapies are prescribed off-label, such as anti-hypertensive agents (labetalol and nicardipine), hemostatic agents (vitamin K and rfVIIa), antiepileptic drugs (phenytoin and lorazepam) and osmotherapy (mannitol 20%) which provide symptomatic treatment but lack superior safety and efficacy. The market does not have any approved therapies. These factors will result in the slow growth of the global brain hemorrhage therapeutics market to 2018.
GlobalData has found that the brain hemorrhage therapeutics market has high unmet needs, suggesting that the current market is not well served by the current treatment options. Moreover, these treatment options are not approved and are used as off-label. The market is dominated by off-label and generic medications which include antihypertensive agents, hemostatic agents, antiepileptic agents, and osmotherapy. Absence of approved therapies for brain hemorrhage clearly establishes that the current brain hemorrhage therapeutics market has high unmet need and there is scope for new entrants exhibiting superior safety and efficacy.
Scope
The report provides information on the key drivers and challenges of the brain hemorrhage therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) brain hemorrhage market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Most of the clinical trials are conducted by academic institutions, currently only GLP-1 CellBeads and PG2 are the drugs sponsored by CellMed/BTG and PhytoHealth Corporation respectively. Of the total number drugs in the pipeline, four drugs are first-in-class and the remaining 12 drugs are generics. The mechanism of action of one drug in phase 0 is unknown. The first-in-class molecules have a distinct advantage over the currently marketed products with regards to better symptomatic management.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the brain hemorrhage therapeutics market.
- Analysis of key recent licensing and partnership agreements in brain hemorrhage therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global brain hemorrhage therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global brain hemorrhage therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global brain hemorrhage therapeutics market landscape? – Identify, understand and capitalize
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
|
|
|
|
